TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36193749

Group type: EXPERIMENTAL
Intervention: Preexisting cardiovascular disease (CVD)
Number of subjects: 5133

Group type: EXPERIMENTAL
Intervention: Myocardial injury on ICU admission
Number of subjects: 5133

Group type: COMPARATOR
Intervention: No preexisting CVD
Number of subjects: 5133
Study: 36194113

Group type: EXPERIMENTAL
Intervention: Single-breath-hold R2* MRI at 1.5 T and 3.0 T
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial R2 MRI method using standardized 1.5-T spin-echo imaging
Number of subjects: 0
Study: 36194207

Group type: EXPERIMENTAL
Intervention: 8-in-1 score
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Parents' recognition of initial manifestations
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Physicians' recognition of initial manifestations
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Diagnostic delay
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Phenotypical characterization
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Neurologic outcomes
Number of subjects: 26
Study: 36194251

Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 36194306

Group type: EXPERIMENTAL
Intervention: Venatech® retrievable IVC filter
Number of subjects: 40
Study: 36194312

Group type: EXPERIMENTAL
Intervention: Stakeholder and Equity Data-Driven Implementation (SEDDI) process
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cultural, linguistic, and health literacy tailoring adaptations
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Facilitation sessions
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: SEDDI
Number of subjects: 4

Group type: COMPARATOR
Intervention: None (control group not explicitly mentioned)
Number of subjects: 4
Study: 36194420

Group type: EXPERIMENTAL
Intervention: Scaling and root planning plus amoxicillin and metronidazole
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Scaling and root planning plus oral hygiene instruction
Number of subjects: 468

Group type: COMPARATOR
Intervention: Supragingival scaling
Number of subjects: 468

Group type: COMPARATOR
Intervention: Oral hygiene instruction plus a copy of radiographs and recommendation to follow-up with a dentist
Number of subjects: 468
Study: 36194458

Group type: EXPERIMENTAL
Intervention: REST video-delivered family therapeutic intervention
Number of subjects: 106
Study: 36194473

Group type: EXPERIMENTAL
Intervention: ECMO during the first wave
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: ECMO during the second wave
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: ECMO during the third wave
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Time from symptoms onset to ECMO
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Changes in CARDS management from first to second wave
Number of subjects: 54
Study: 36194483

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 11

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 11
Study: 36194670

Group type: EXPERIMENTAL
Intervention: Camrelizumab (CC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy (CA)
Number of subjects: 0
Study: 36194864

Group type: EXPERIMENTAL
Intervention: Low-dose multiplayer virtual reality telegaming program (2 supervised 1-hour sessions per week for 1 month)
Number of subjects: 12
Study: 36194890

Group type: EXPERIMENTAL
Intervention: Psychosocial interventions for sexual abuse and violence
Number of subjects: 37
Study: 36195441

Group type: EXPERIMENTAL
Intervention: Intravenous infliximab (IFX) 3 mg/kg
Number of subjects: 225

Group type: COMPARATOR
Intervention: Saline placebo (PLBO)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Intravenous infliximab (IFX)
Number of subjects: 225
Study: 36195591

Group type: EXPERIMENTAL
Intervention: Maltreatment (measured by Childhood Trauma questionnaire and Adverse Childhood Experiences questionnaire)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Household Dysfunction
Number of subjects: 82
Study: 36195836

Group type: EXPERIMENTAL
Intervention: High EVI1 expression in TNBC patients
Number of subjects: 993
Study: 36195993

Group type: EXPERIMENTAL
Intervention: Nitrate treatment
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: CAD-HF patients with PH
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: HFrEF-PH patients
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: CAD-HF patients with enlarged left ventricular end-diastolic diameter and reduced hemoglobin
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Elevated creatinine and mean pulmonary arterial pressure (mPAP), diastolic pressure gradient (DPG) ≥7 mmHg, and previous myocardial infarction (MI)
Number of subjects: 182
Study: 36196048

Group type: EXPERIMENTAL
Intervention: Gene therapy-based clinical trials (NCT04693598 and NCT04771416) for Krabbe disease
Number of subjects: 0
Study: 36196060

Group type: EXPERIMENTAL
Intervention: Time-to-diuretics (intravenous furosemide) administered within the first 24 hours, median time 67 minutes (25th-75th percentiles 17-190 minutes)
Number of subjects: 15078

Group type: EXPERIMENTAL
Intervention: Time-to-diuretics administered between hospital arrival and 8 hours post-hospital arrival
Number of subjects: 15078
Study: 36196609

Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA COVID-19 vaccine
Number of subjects: 51
Study: 36196777

Group type: EXPERIMENTAL
Intervention: Fenfluramine (0.2 mg/kg/day, titrated by effectiveness and tolerability)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 247
Study: 36196899

Group type: EXPERIMENTAL
Intervention: Nebulized morphine (nMOR) 10 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: nMOR
Number of subjects: 75
Study: 36197049

Group type: EXPERIMENTAL
Intervention: IL-17 expression in perifollicular fibrosis in LPP
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IL-17 expression in lichenoid inflammatory infiltrate in LPP
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chronic telogen effluvium biopsies
Number of subjects: 40
Study: 36197159

Group type: EXPERIMENTAL
Intervention: Participation group
Number of subjects: 1804

Group type: COMPARATOR
Intervention: Nonparticipation group
Number of subjects: 1804
Study: 36197507

Group type: EXPERIMENTAL
Intervention: CT-scan imaging
Number of subjects: 2380

Group type: COMPARATOR
Intervention: Other diagnostics
Number of subjects: 2380

Group type: EXPERIMENTAL
Intervention: Radical nephroureterectomy
Number of subjects: 2380
Study: 36197536

Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Worsening endocrine symptoms
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Worsening physical function
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Prior mastectomy
Number of subjects: 300
Study: 36197661

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg orally twice daily
Number of subjects: 8
Study: 36197682

Group type: EXPERIMENTAL
Intervention: Neoadjuvant intensity-modulated radiotherapy (IMRT) followed by hepatectomy
Number of subjects: 38
Study: 36197706

Group type: COMPARATOR
Intervention: Bolstered usual care (literature on antiretroviral therapy adherence promotion and stigma reduction)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Multiple family groups for HIV stigma reduction plus family economic empowerment (MFG-HIVSR plus FEE)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Group-based HIV stigma reduction for educators (GED-HIVSR)
Number of subjects: 840
Study: 36197809

Group type: EXPERIMENTAL
Intervention: Retrograde intramedullary nail (RIMN)
Number of subjects: 753

Group type: COMPARATOR
Intervention: Locking plates
Number of subjects: 753
Study: 36198179

Group type: EXPERIMENTAL
Intervention: IVIG (2.0 g/kg every 4 weeks for 16 weeks)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 36198473

Group type: EXPERIMENTAL
Intervention: PRPP intervention (9 sessions)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Delayed intervention phases
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Goal Attainment Scaling and Barthel Index
Number of subjects: 6
Study: 36198471

Group type: EXPERIMENTAL
Intervention: Machine learning (ML) algorithm for reading WB-MRI scans
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: ML-assisted reading
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Experienced readers with ML
Number of subjects: 633

Group type: COMPARATOR
Intervention: Experienced readers without ML
Number of subjects: 633
Study: 36198565

Group type: EXPERIMENTAL
Intervention: Radiolabeled peptide pair
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36198701

Group type: EXPERIMENTAL
Intervention: Non-invasive spinal neuromodulation during activity-based neurorehabilitation therapy (ABNT), 2x/week for 8 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Activity-based neurorehabilitation therapy (ABNT) alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Safety endpoint
Number of subjects: 16
Study: 36199536

Group type: EXPERIMENTAL
Intervention: Laparoscopic lower mediastinal lymphadenectomy along with total or proximal gastrectomy
Number of subjects: 1036

Group type: COMPARATOR
Intervention: Open lower mediastinal lymphadenectomy along with total or proximal gastrectomy
Number of subjects: 1036
Study: 36200380

Group type: EXPERIMENTAL
Intervention: Frontline treatment for Hodgkin lymphoma
Number of subjects: 0
Study: 36200417

Group type: EXPERIMENTAL
Intervention: Tucidinostat 40 mg twice per week (BIW)
Number of subjects: 55
Study: 36200421

Group type: EXPERIMENTAL
Intervention: HBI0101 (150x10^6 CAR T cells)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HBI0101 (450x10^6 CAR T cells)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HBI0101 (800x10^6 CAR T cells)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HBI0101 (all cohorts)
Number of subjects: 20
Study: 36200629

Group type: EXPERIMENTAL
Intervention: Temporal dynamics of serum levels of Glial Fibrillary Acidic Protein (GFAP)
Number of subjects: 0
Study: 36200668

Group type: EXPERIMENTAL
Intervention: Spartalizumab monotherapy
Number of subjects: 0
Study: 36200701

Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Acute Omicron infection (control group)
Number of subjects: 15
Study: 36201124

Group type: EXPERIMENTAL
Intervention: High disease activity
Number of subjects: 1915

Group type: EXPERIMENTAL
Intervention: Treatment with glucocorticoids
Number of subjects: 1915

Group type: EXPERIMENTAL
Intervention: Treatment with rituximab
Number of subjects: 1915

Group type: EXPERIMENTAL
Intervention: Public health insurance
Number of subjects: 1915

Group type: EXPERIMENTAL
Intervention: Mestizos ethnicity
Number of subjects: 1915

Group type: EXPERIMENTAL
Intervention: Older age, male gender, higher disease activity, presence of comorbidities
Number of subjects: 1915

Group type: COMPARATOR
Intervention: Hospitalization
Number of subjects: 1915

Group type: COMPARATOR
Intervention: ICU admission
Number of subjects: 1915

Group type: COMPARATOR
Intervention: Death due to COVID-19
Number of subjects: 1915

Group type: COMPARATOR
Intervention: Non-invasive mechanical ventilation (NIMV) or high flow oxygen devices
Number of subjects: 1915

Group type: COMPARATOR
Intervention: Invasive mechanical ventilation (IMV)
Number of subjects: 1915
Study: 36201226

Group type: EXPERIMENTAL
Intervention: Universal access to PrEP offered to adolescents and adults at elevated risk during population-level HIV testing
Number of subjects: 0
Study: 36201380

Group type: EXPERIMENTAL
Intervention: Positive psychology-motivational interviewing telephone intervention
Number of subjects: 58

Group type: COMPARATOR
Intervention: Physical activity education control
Number of subjects: 58
Study: 36201392

Group type: EXPERIMENTAL
Intervention: Shared Decision-Making (SDM) system
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 17
Study: 36201545

Group type: EXPERIMENTAL
Intervention: Fluoroquinolones (FQ)
Number of subjects: 40981

Group type: EXPERIMENTAL
Intervention: Trimethoprim without sulfamethoxazole
Number of subjects: 40981

Group type: COMPARATOR
Intervention: Fluoroquinolones and other antibiotics (post-hoc analysis excluding ophthalmic drops)
Number of subjects: 40981

Group type: COMPARATOR
Intervention: Oral Fluoroquinolones
Number of subjects: 40981
Study: 36201564

Group type: EXPERIMENTAL
Intervention: Integrative care practices (ICPs)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Children from migrant families
Number of subjects: 89
Study: 36202450

Group type: EXPERIMENTAL
Intervention: Intraplaque hemorrhage (IPH)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Total plaque volume
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Addition of IPH and total plaque volume to the ECST risk score
Number of subjects: 244
Study: 36202455

Group type: EXPERIMENTAL
Intervention: Change in perivascular adipose tissue (PVAT) density
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Total plaque volume (PV)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: PVAT density
Number of subjects: 474
Study: 36202537

Group type: EXPERIMENTAL
Intervention: Echocardiographic screening
Number of subjects: 0
Study: 36202561

Group type: EXPERIMENTAL
Intervention: Cardioband Tricuspid Valve Reconstruction System
Number of subjects: 37
Study: 36202825

Group type: EXPERIMENTAL
Intervention: ChARMin assessments (active and passive Range of Motion, Strength, Resistance to Passive Movement, Quality of Movement, Circle, and Workspace)
Number of subjects: 30
Study: 36202865

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the radial and median nerves using epineural electrodes
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intuitive interface controlled by voluntary actions
Number of subjects: 2
Study: 36202997

Group type: EXPERIMENTAL
Intervention: mRNA-1273.211 50-µg booster dose
Number of subjects: 895

Group type: EXPERIMENTAL
Intervention: mRNA-1273.211 100-µg booster dose
Number of subjects: 895

Group type: COMPARATOR
Intervention: mRNA-1273 50-µg booster dose
Number of subjects: 895
Study: 36203049

Group type: EXPERIMENTAL
Intervention: prehospital thrombolysis
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: in-hospital thrombolysis
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: primary percutaneous coronary intervention (pPCI)
Number of subjects: 146

Group type: COMPARATOR
Intervention: overall performance
Number of subjects: 146

Group type: COMPARATOR
Intervention: system improvements
Number of subjects: 146
Study: 36203163

Group type: EXPERIMENTAL
Intervention: Quantitative comorbidity measures based on the 5-year history of number of hospital admissions, length of stay, and time since latest admission in 36 comorbidity categories
Number of subjects: 188965

Group type: COMPARATOR
Intervention: Charlson comorbidity index (CCI)
Number of subjects: 188965

Group type: COMPARATOR
Intervention: Simplified Acute Physiology Score (SAPS3)
Number of subjects: 188965

Group type: EXPERIMENTAL
Intervention: Quantitative comorbidity measures
Number of subjects: 188965
Study: 36203210

Group type: COMPARATOR
Intervention: Deep-hypo
Number of subjects: 64

Group type: COMPARATOR
Intervention: Mild-hypo
Number of subjects: 64
Study: 36203544

Group type: EXPERIMENTAL
Intervention: Abatacept (10 mg/kg, maximum dose 1000 mg) plus standard of care (SOC)
Number of subjects: 1019

Group type: COMPARATOR
Intervention: Placebo plus standard of care (SOC)
Number of subjects: 1019
Study: 36203563

Group type: EXPERIMENTAL
Intervention: BNT162b2 (0.3ml intramuscular, homologous)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CoronaVac (0.5ml intramuscular, homologous)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CoronaVac (0.5ml intradermal)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: BNT162b2 (2 doses intramuscular, 1 dose intradermal)
Number of subjects: 39
Study: 36203760

Group type: EXPERIMENTAL
Intervention: Portable sauna bath (30-min, 45°C sauna bath, daily for 10 days)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Portable sauna bath
Number of subjects: 51
Study: 36203789

Group type: EXPERIMENTAL
Intervention: Acoustocerebrography (ACG) system
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acoustocerebrography (ACG) data
Number of subjects: 20
Study: 36203975

Group type: EXPERIMENTAL
Intervention: 0.65 mg/kg r-tPA
Number of subjects: 2666

Group type: COMPARATOR
Intervention: 0.90 mg/kg r-tPA
Number of subjects: 2666
Study: 36203998

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 310
Study: 36204243

Group type: EXPERIMENTAL
Intervention: Venglustat 8 mg once daily
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Venglustat 15 mg once daily
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Venglustat (preferred dose based on stage 1 safety data)
Number of subjects: 240
Study: 36204554

Group type: EXPERIMENTAL
Intervention: Wearable sensory prosthesis (Walkasins)
Number of subjects: 44
Study: 36204759

Group type: EXPERIMENTAL
Intervention: Olfactory stimulation with cognitive training (OS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Board game training (BG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 30
Study: 36204779

Group type: EXPERIMENTAL
Intervention: WhatsApp supervision for lay leaders
Number of subjects: 9
Study: 36204820

Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel) at a targeted dose of 0.75 × 10^6 CAR T cells/kg
Number of subjects: 97
Study: 36205071

Group type: EXPERIMENTAL
Intervention: HPV Vaccinations at Acute Visits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subsequent Adolescent Preventive Visits
Number of subjects: 0
Study: 36205505

Group type: EXPERIMENTAL
Intervention: Patients with myelofibrosis (MF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with essential thrombocythemia (ET)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women with MF or ET
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall symptom burden in MF and ET cohorts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with lower risk MF and low- or high-risk ET
Number of subjects: 0
Study: 36205514

Group type: EXPERIMENTAL
Intervention: AVT02 administered subcutaneously via autoinjector (AI), 40 mg, for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AVT02 administered via prefilled syringe in the extension phase
Number of subjects: 0
Study: 36205563

Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 0
Study: 36205910

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg (FIL200)
Number of subjects: 4695

Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg (FIL100)
Number of subjects: 4695

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4695
Study: 36205913

Group type: EXPERIMENTAL
Intervention: Foot Posture Index (FPI-6)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: New York Posture Rating (NYPR)
Number of subjects: 38
Study: 36206041

Group type: EXPERIMENTAL
Intervention: Pemigatinib, 13.5 mg orally once daily for 14 consecutive days, followed by 7 days off therapy
Number of subjects: 107
Study: 36206189

Group type: EXPERIMENTAL
Intervention: FLASH therapy (8 Gy in a single fraction delivered at ≥40 Gy per second)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: FLASH therapy
Number of subjects: 10
Study: 36206298

Group type: EXPERIMENTAL
Intervention: Taxane-based chemotherapy
Number of subjects: 13
Study: 36206609

Group type: EXPERIMENTAL
Intervention: Ribociclib plus letrozole
Number of subjects: 526
Study: 36207039

Group type: EXPERIMENTAL
Intervention: Lyotube Stain 468
Number of subjects: 103

Group type: COMPARATOR
Intervention: Laboratory-developed liquid reagent cocktail
Number of subjects: 103
Study: 36207229

Group type: EXPERIMENTAL
Intervention: Allostatic load measurement
Number of subjects: 0
Study: 36207366

Group type: EXPERIMENTAL
Intervention: High-calorie meal test
Number of subjects: 101
Study: 36207609

Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy (PtCT) in gBRCA1/2m carriers (N=300)
Number of subjects: 1222

Group type: COMPARATOR
Intervention: Non-platinum-based chemotherapy (non-PtCT) in gBRCA1/2m carriers (N=300)
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy (PtCT) in gBRCA1/2wt patients (N=922)
Number of subjects: 1222

Group type: COMPARATOR
Intervention: Non-platinum-based chemotherapy (non-PtCT) in gBRCA1/2wt patients (N=922)
Number of subjects: 1222
Study: 36207706

Group type: EXPERIMENTAL
Intervention: Health promotion program implemented in DMCCs
Number of subjects: 29191
Study: 36207737

Group type: EXPERIMENTAL
Intervention: In-ICU red blood cells transfusion
Number of subjects: 1551
Study: 36208004

Group type: EXPERIMENTAL
Intervention: Patients with vitiligo
Number of subjects: 142
Study: 36208017

Group type: EXPERIMENTAL
Intervention: LMB-100 with nab-paclitaxel (Arm A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: LMB-100 (Arm B)
Number of subjects: 40
Study: 36208712

Group type: EXPERIMENTAL
Intervention: Endoscopic release superficial to the transverse carpal ligament (ERSTCL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (conventional Chow endoscopic release)
Number of subjects: 100
Study: 36208796

Group type: EXPERIMENTAL
Intervention: Fully covered self-expandable metal stent (FCSEMS)
Number of subjects: 67
Study: 36209063

Group type: EXPERIMENTAL
Intervention: Confirm Rx™ ICM in supine posture
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Confirm Rx™ ICM in parasternally oriented position (n=44)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Confirm Rx™ ICM in 45°-relative-to-sternum orientation (n=46)
Number of subjects: 99
Study: 36209118

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 4055

Group type: COMPARATOR
Intervention: DPP4i
Number of subjects: 4055

Group type: EXPERIMENTAL
Intervention: Study medication (all types)
Number of subjects: 4055

Group type: EXPERIMENTAL
Intervention: Treatment guidelines adherence
Number of subjects: 4055
Study: 36209149

Group type: EXPERIMENTAL
Intervention: eReferral to state tobacco quitlines
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: eReferral implementation strategies
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Staff survey
Number of subjects: 11